The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PRPH | -62.74% | -96.26% | -48.13% | +5% |
| S&P | +13.19% | +87.83% | +13.42% | +1,509% |
ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. It operates through the Diagnostic Services and Consumer Products segment. The Diagnostic Services segment includes COVID-19 and other diagnostic testing services. The Consumer Products segment consists of the manufacturing, retail customers, and personal genomics products and services. The company was founded by Guy J. Quigley and Charles A. Phillips in July 1989 and is headquartered in Garden City, NY.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.25M | -49.6% |
| Gross Profit | $0.73M | 254.2% |
| Gross Margin | 58.86% | 78.1% |
| Market Cap | $16.26M | -79.6% |
| Market Cap / Employee | $0.14M | 0.0% |
| Employees | 113 | 0.0% |
| Net Income | -$4.47M | 27.3% |
| EBITDA | -$1.10M | 82.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.17M | -92.9% |
| Accounts Receivable | $20.09M | -39.0% |
| Inventory | 0.8 | -78.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.33M | -87.6% |
| Short Term Debt | $5.54M | -31.8% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Return On Assets | -30.25% | 0.0% |
| Return On Invested Capital | -38.99% | -33.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$0.25M | 94.9% |
| Operating Free Cash Flow | -$0.25M | 94.9% |
| Metric | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.68 | 1.21 | 0.20 | 1.04 | -55.92% |
| Price to Sales | 1.84 | 4.07 | 4.39 | 3.62 | - |
| Price to Tangible Book Value | 2.70 | 2.05 | 0.34 | 12.87 | 250.76% |
| Enterprise Value to EBITDA | -16.96 | -13.75 | -13.67 | -21.79 | 2.46% |
| Return on Equity | -29.7% | -45.0% | -50.9% | -58.7% | - |
| Total Debt | $26.82M | $29.59M | $14.01M | $7.87M | -66.30% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
